OS treatment effect of tisagenlecleucel versus blinatumomab
| Method . | HR . | 95% CI . | P . |
|---|---|---|---|
| Unadjusted HR | |||
| Univariate Cox regression | 0.26 | 0.16-0.43 | <.001 |
| Marginal HR (adjusted) | |||
| Cox regression with sIPTW | 0.31 | 0.19-0.50 | <.001 |
| Cox regression with trimmed sIPTW | 0.31 | 0.19-0.50 | <.001 |
| Conditional HR (adjusted) | |||
| Cox regression stratified by quintiles of propensity score | 0.32 | 0.19-0.55 | <.001 |
| Cox regression adjusting for prognostic factors | 0.26 | 0.16-0.45 | <.001 |
| Cox regression adjusting for prognostic factors and propensity score | 0.26 | 0.15-0.44 | <.001 |
| Method . | HR . | 95% CI . | P . |
|---|---|---|---|
| Unadjusted HR | |||
| Univariate Cox regression | 0.26 | 0.16-0.43 | <.001 |
| Marginal HR (adjusted) | |||
| Cox regression with sIPTW | 0.31 | 0.19-0.50 | <.001 |
| Cox regression with trimmed sIPTW | 0.31 | 0.19-0.50 | <.001 |
| Conditional HR (adjusted) | |||
| Cox regression stratified by quintiles of propensity score | 0.32 | 0.19-0.55 | <.001 |
| Cox regression adjusting for prognostic factors | 0.26 | 0.16-0.45 | <.001 |
| Cox regression adjusting for prognostic factors and propensity score | 0.26 | 0.15-0.44 | <.001 |
An HR <1 indicates that tisagenlecleucel is associated with a lower hazard of death than blinatumomab after adjusting for prognostic factors.